Endo Acquires Rights to Trimel’s Natesto Testosterone Nasal Gel

Endo International has announced it acquired the rights to Natesto, a testosterone nasal gel that acts as replacement therapy in men diagnosed with hypogonadism, from Trimel BioPharma SRL. Natesto, approved by the U.S. Food and Drug Administration (FDA) earlier this year, is an androgen that can be used as a therapy for patients suffering from a